Nancy Lin, Breast Cancer Specialist and Director of EMBRACE MBC Program at Dana-Farber Cancer Institute, shared a post on X about a paper she co-authored with colleagues published in Breast Cancer Research:

“Now published!

Phase 1/2 palazestrant (OP-1250) monotherapy in ER+ MBC

at RP2D 120 mg/d
mPFS 4.8 mo overall, 5.6 mo in ESR1mut
in ‘EMERALD eligible’ patients (1-2 prior ET for MBC +/- 1L chemo), mPFS > 7 mo regardless of ESR1 status.”

Title: Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

Authors: Erika P. Hamilton, Manish R. Patel, Virginia F. Borges, Jane L. Meisel, Meena Okera, Carlos A. Alemany, Timothy J. Pluard, Robert Wesolowski, Dhanusha Sabanathan, Kathy D. Miller, Alison K. Conlin, Nicole McCarthy, Morena Shaw, Margaret Tonda, Mark Shilkrut, and Nancy U. Lin.

You can read the Full Article in Breast Cancer Research.

Nancy Lin: Palazestrant Demonstrates More Than 7 Months mPFS in EMERALD-Eligible ER+ MBC Patients